Table 1.
Clinical characteristics of subjects studied.
| 0–3M (n=17) | 4–6M (n=23) | 7–9M (n=8) | 10–14M (n=17) | 15–17M (n=7) | 18M+ (n=19) | |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age (months), median (IQR) | 2.9 (2.6–3.5) | 6 (5.4–6.1) | 8.4 (7.9–9.6) | 12.8 (11.3–13.9) | 17.5 (16.6–17.6) | 28.3 (20.3–33.9) |
| Weight at study (kg), median (IQR) | 5.7 (4.8–6.1) | 7.7 (6.8–8.2) | 8.1 (8–9) | 10.3 (9.2–11.4) | 11.1 (10.8–12) | 13.9 (12.4–15.2) |
| Sex (male), % (n) | 76.5 (13) | 91.3 (21) | 50 (4) | 88.2 (15) | 85.7 (6) | 78.9 (15) |
| Anaesthetic management | ||||||
| Duration of anaesthesia (min), median (IQR) | 103 (86–140) | 94 (77–170) | 148.5 (100.8–184.3) | 95 (86–132) | 133 (106.5–174.5) | 112 (67–169.5) |
| Propofol, % (n) | 64.7 (11) | 47.8 (11) | 37.5 (3) | 70.6 (12) | 0 (0) | 52.9 (9) |
| Local anaesthetic agents, % (n) | 82.3 (14) | 95.6 (22) | 87.5 (7) | 82.4 (14) | 57.1 (4) | 52.9 (9) |
| Opioid agents, % (n) | 82.3 (14) | 65.2 (15) | 87.5 (7) | 94.1 (16) | 85.7 (6) | 82.4 (14) |
| Neuromuscular blocking agents, % (n) | 70.6 (12) | 34.8 (8) | 37.5 (3) | 52.9 (9) | 42.9 (3) | 23.5 (4) |
| Maintenance epoch | ||||||
| End-tidal sevoflurane (%), mean (SD) | 2.3 (0.7) | 2.6 (0.6) | 2.3 (0.3) | 2.5 (0.6) | 2.7 (0.6) | 2.3 (0.4) |
IQR, interquartile range; SD, standard deviation.